Ain Holdings Inc. revised consolidated earnings guidance for the year ending April 30, 2018. For the year, the company revised net sales of JPY 267,500 million, operating income of JPY 18,000 million, ordinary income of JPY 18,500 million, profit attributable to owners of parent of JPY 9,200 million or JPY 269.96 per share compared to previously expected net sales of JPY 267,500 million, operating income of JPY 16,600 million, ordinary income of JPY 17,000 million, profit attributable to owners of parent of JPY 8,900 million or JPY 261.15 per share. Reason for revision was in dispensing pharmacy business, drug price per prescription has exceeded the initial forecasts. In addition, profit ratio has improved supported by lower costs due to greater business efficiency both in dispensing pharmacy business and in drug and cosmetic store business. In drug and cosmetic store business, the company expects profitability in full year by the rise of sales at existing stores.